Royal London European Growth Fund ARegister to Unlock Ratings |
Performance History | 30/09/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 10.2 | 19.5 | -8.8 | 14.0 | 5.0 | |
+/-Cat | 0.8 | 4.1 | -0.1 | 0.5 | -0.5 | |
+/-B’mrk | 2.2 | 2.3 | -1.3 | -1.0 | -1.7 | |
Category: Europe ex-UK Equity | ||||||
Category Benchmark: Morningstar DM Eur xUK TME ... |
Key Stats | ||
NAV 11/10/2024 | GBX 1337.00 | |
Day Change | 0.38% | |
Morningstar Category™ | Europe ex-UK Equity | |
IA (formerly IMA) Sector | Europe Excluding UK | |
ISIN | GB00B52DGB49 | |
Fund Size (Mil) 30/09/2024 | GBP 2410.27 | |
Share Class Size (Mil) 30/09/2024 | GBP 57.93 | |
Max Initial Charge | - | |
Ongoing Charge 07/05/2024 | 1.05% |
Investment Objective: Royal London European Growth Fund A |
The Fund’s investment objective is to achieve a total return over the medium term, which should be considered as a period of 3-5 years, by predominantly investing in the shares of European companies, not including the UK, listed on European stock exchanges. At least 80% of the Fund will be invested in the shares of European companies, not including the UK. European companies are those domiciled in Continental Europe, or which have significant European business operations. The Fund will typically invest in larger companies worth €3 billion or more. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Steve Bolton 23/10/2017 | ||
Inception Date 10/03/1987 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
FTSE World Eur Ex UK TR GBP | Morningstar DM Eur xUK TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Royal London European Growth Fund A | 31/08/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk AS Class B | Healthcare | 5.41 |
Roche Holding AG | Healthcare | 5.01 |
SAP SE | Technology | 4.61 |
ASML Holding NV | Technology | 4.46 |
Lvmh Moet Hennessy Louis Vuitton SE | Consumer Cyclical | 4.08 |
Increase Decrease New since last portfolio | ||
Royal London European Growth Fund A |